Trellus Health PLC (GB:TRLS) has released an update.
Trellus Health PLC has made significant strides in its chronic condition management programs, particularly for IBD, with the signing of major B2B2C agreements and a promising partnership with a large US health plan. The company concluded its pilot programs successfully and entered into licensing agreements with pharmaceutical companies, illustrating the value of its proprietary methodology. Despite a net cash decrease, Trellus Health’s careful cash management has extended its operational runway into mid-2025, with a focus on continued commercial growth and improved health outcomes.
For further insights into GB:TRLS stock, check out TipRanks’ Stock Analysis page.
